SALARIUS PHARMACEUTICALS INC (SLRX) Stock Fundamental Analysis

NASDAQ:SLRX • US79400X5032

0.84 USD
+0.19 (+29.23%)
At close: Jan 7, 2026
0.835 USD
-0.01 (-0.6%)
After Hours: 1/7/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Taking everything into account, SLRX scores 1 out of 10 in our fundamental rating. SLRX was compared to 520 industry peers in the Biotechnology industry. While SLRX seems to be doing ok healthwise, there are quite some concerns on its profitability. SLRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • SLRX had negative earnings in the past year.
  • In the past year SLRX has reported a negative cash flow from operations.
  • SLRX had negative earnings in each of the past 5 years.
  • In the past 5 years SLRX always reported negative operating cash flow.
SLRX Yearly Net Income VS EBIT VS OCF VS FCFSLRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • SLRX has a Return On Assets of -82.08%. This is in the lower half of the industry: SLRX underperforms 68.68% of its industry peers.
  • With a Return On Equity value of -117.81%, SLRX perfoms like the industry average, outperforming 41.51% of the companies in the same industry.
Industry RankSector Rank
ROA -82.08%
ROE -117.81%
ROIC N/A
ROA(3y)-196.87%
ROA(5y)-130.59%
ROE(3y)-303.46%
ROE(5y)-195.66%
ROIC(3y)N/A
ROIC(5y)N/A
SLRX Yearly ROA, ROE, ROICSLRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • SLRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLRX Yearly Profit, Operating, Gross MarginsSLRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • SLRX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for SLRX has been increased compared to 5 years ago.
  • SLRX has a worse debt/assets ratio than last year.
SLRX Yearly Shares OutstandingSLRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20K 40K 60K 80K
SLRX Yearly Total Debt VS Total AssetsSLRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -19.94, we must say that SLRX is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of SLRX (-19.94) is worse than 82.45% of its industry peers.
  • SLRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.94
ROIC/WACCN/A
WACCN/A
SLRX Yearly LT Debt VS Equity VS FCFSLRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • SLRX has a Current Ratio of 3.28. This indicates that SLRX is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 3.28, SLRX is not doing good in the industry: 61.13% of the companies in the same industry are doing better.
  • SLRX has a Quick Ratio of 3.28. This indicates that SLRX is financially healthy and has no problem in meeting its short term obligations.
  • SLRX has a Quick ratio of 3.28. This is comparable to the rest of the industry: SLRX outperforms 42.08% of its industry peers.
Industry RankSector Rank
Current Ratio 3.28
Quick Ratio 3.28
SLRX Yearly Current Assets VS Current LiabilitesSLRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • SLRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.10%, which is quite impressive.
EPS 1Y (TTM)68.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • SLRX is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.17% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-126.98%
EPS Next 2Y-3.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLRX Yearly Revenue VS EstimatesSLRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2026 2M 4M 6M 8M 10M
SLRX Yearly EPS VS EstimatesSLRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 -50K -100K -150K

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • SLRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SLRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLRX Price Earnings VS Forward Price EarningsSLRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLRX Per share dataSLRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

  • A cheap valuation may be justified as SLRX's earnings are expected to decrease with -3.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.17%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for SLRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SALARIUS PHARMACEUTICALS INC

NASDAQ:SLRX (1/7/2026, 8:00:02 PM)

After market: 0.835 -0.01 (-0.6%)

0.84

+0.19 (+29.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-19
Inst OwnersN/A
Inst Owner Change14652%
Ins OwnersN/A
Ins Owner Change4.16%
Market Cap4.92M
Revenue(TTM)N/A
Net Income(TTM)-5.00M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.16
P/tB 1.16
EV/EBITDA N/A
EPS(TTM)-39.18
EYN/A
EPS(NY)-4.39
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.76
OCFYN/A
SpS0
BVpS0.72
TBVpS0.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -82.08%
ROE -117.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-196.87%
ROA(5y)-130.59%
ROE(3y)-303.46%
ROE(5y)-195.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.28
Quick Ratio 3.28
Altman-Z -19.94
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.05%
EPS Next Y-126.98%
EPS Next 2Y-3.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y72.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.38%
OCF growth 3YN/A
OCF growth 5YN/A

SALARIUS PHARMACEUTICALS INC / SLRX FAQ

Can you provide the ChartMill fundamental rating for SALARIUS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 1 / 10 to SLRX.


What is the valuation status for SLRX stock?

ChartMill assigns a valuation rating of 0 / 10 to SALARIUS PHARMACEUTICALS INC (SLRX). This can be considered as Overvalued.


What is the profitability of SLRX stock?

SALARIUS PHARMACEUTICALS INC (SLRX) has a profitability rating of 0 / 10.


How sustainable is the dividend of SALARIUS PHARMACEUTICALS INC (SLRX) stock?

The dividend rating of SALARIUS PHARMACEUTICALS INC (SLRX) is 0 / 10 and the dividend payout ratio is 0%.